Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Journal Article

Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

Full Text

Duke Authors

Cited Authors

  • Keshelava, N; Houghton, PJ; Morton, CL; Lock, RB; Carol, H; Keir, ST; Maris, JM; Reynolds, CP; Gorlick, R; Kolb, EA; Wu, J; Smith, MA

Published Date

  • September 2009

Published In

Volume / Issue

  • 53 / 3

Start / End Page

  • 505 - 508

PubMed ID

  • 19418547

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.21988

Language

  • eng

Conference Location

  • United States